EP
ZVRA icon

Essential Partners’s Zevra Therapeutics ZVRA Stock Holding History

Essential Partners’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.27K Sell
228
-596
-72% -$6.63K ﹤0.01% 1750
2026
Q1 		$7.68K Hold
824
– – ﹤0.01% 1374
2025
Q4 		$7.38K Sell
824
-4
-0.5% -$38 ﹤0.01% 1273
2025
Q3 		$7.87K Buy
+828
New +$8.3K ﹤0.01% 1259

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Essential Partners's ZVRA Position: Q2 2026 in Review

Essential Partners reduced its Zevra Therapeutics (ZVRA) stake by 72% in Q2 2026, selling an estimated $6.63K and leaving 228 shares worth $3.27K. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

Essential Partners first reported a position in ZVRA in Q3 2025 and has held it in 4 quarters since. The position peaked at $7.87K in Q3 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Essential Partners held 228 shares of Zevra Therapeutics worth $3.27K as of Q2 2026.
  • Essential Partners sold 596 Zevra Therapeutics shares in Q2 2026, an estimated $6.63K.
  • Zevra Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1750 holding.
  • Essential Partners first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Zevra Therapeutics position peaked at $7.87K in Q3 2025.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.